Lipodystrophy: The Metabolic Link of HIV Infection with Insulin-Resistance Syndrome by Freitas, Paula et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 12
Lipodystrophy: The Metabolic Link of HIV Infection
with Insulin-Resistance Syndrome
Paula Freitas, Davide Carvalho, Selma Souto,
António Sarmento and José Luís Medina
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52685
1. Introduction
Human lipodystrophies are a heterogeneous group of diseases characterized by generalized
or partial fat loss. If localized, they are often associated with fat hypertrophy in other depots,
varying according to the type of lipodystrophy. Lipodystrophies can be genetic, which is
usually uncommon, or acquired. Genetic lipodystrophy is generally related to severe meta‐
bolic alterations including insulin resistance (IR) and its associated complications, such as
glucose intolerance and diabetes, dyslipidemia, hepatic steatosis, polycystic ovaries, acan‐
thosis nigricans and early cardiovascular (CV) complications [1, 2]. The autosomal recessive
congenital generalized lipodystrophy (CGL) and autosomal dominant familiar partial lipo‐
dystrophy (FPL) are the two most common types of genetic lipodystrophy [2]. Lipodystro‐
phies have been reported in the medical literature for more than 100 years [2, 3]. However,
only 13 years ago, new lipodystrophy syndromes were recognized, being associated with vi‐
ral infection, specifically with the human immunodeficiency virus, in patients treated with
combined antiretroviral therapy (cART) [4]. This has become the most frequent form of lipo‐
dystrophy [2]. Some first-generation antiretroviral drugs used in HIV patients are strongly
related with peripheral lipoatrophy and metabolic alterations [1].
Human lipodystrophies leads to severe metabolic alterations resulting in premature CV com‐
plications. On the other hand, high adiposity, such as seen in obesity, also increases metabolic
alterations and leads to increased CV risk. So, it seems that the two extremes, the absence or the
excess of fat mass, are associated with the same metabolic and CV complications. The conse‐
quences of increased fat depots are markedly dependent upon their localization. Adipose tis‐
sue in the lower part of the body is able to expand and can therefore accumulate excessive
energy from diet, store triglycerides, and it appears to be protective at the metabolic level [5].
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By contrast, accumulation of fat in the upper part of the body is deleterious. Therefore, de‐
creased peripheral subcutaneous adipose tissue (SAT), and even more increased visceral adi‐
pose tissue (VAT), are strongly associated with metabolic alterations and IR [1].
With regards to the HIV-associated lipodystrophy, the available data suggest that this con‐
dition is caused by a complex interaction involving side effects of cART, disease related in‐
flammation, and individual characteristics [6]. At present, HIV-infected patients are exposed
to an increased metabolic risk like the general population, resulting from ageing, increased
weight and fat gain, high fat and energy food and marked sedentariness. Moreover, a num‐
ber of additional factors could worsen their metabolic profile, such as the ongoing HIV in‐
fection, the presence of lipodystrophy and the continuous use of antiretroviral drugs [7].
HIV-associated lipodystrophy is also associated with premature aging [8]resembling meta‐
bolic laminopathies and progeria [1]. Premature aging of HIV-infected patients affects bone,
brain, vascular wall, muscles, kidney and liver, and results of the combined effects of long-
term HIV-1 infection, depleted immune responses, the toxicity of some antiretrovirals and
lipodystrophy. Cellular senescence seems to result from prelamin-A accumulation induced
by some antiretroviral drugs, mitochondrial dysfunction and oxidative stress. In addition,
increased cytokine release in lipodystrophy further contributes to premature aging and
therefore, to early CV and hepatic disease risks [9].
We focus on adipocytes dysregulation in genetic and acquired lipodystrophy, with empha‐
sis on the most common form, HIV-lipodystrophy, fromthe etiology to its complications.
2. Adipose tissue biology –Three different adipose tissue compartments
Adipocytes are a dynamic and highly regulated population of cells. Adipose tissue is char‐
acterized by a marked cellular heterogeneity among its cellular components: adipocytes,
preadipocytes, fibroblasts, macrophages, lymphocytes, endothelial cells and multipotent
stem cells, able to differentiate into several cell types. Adipose tissue can release regulatory
factors (adipokines, cytokines, or chemokines) or metabolites (FFAs) capable of influencing
other surrounding cells, thus establishing active cross-talk among cells within adipose tis‐
sue. [9]. Overall, fat tissue consists of approximately one third mature adipocytes. The re‐
maining two thirds are a combination of small blood vessels, nerve tissue, fibroblasts and
preadipocytes in various stages of development. Preadipocytes have the ability to prolifer‐
ate and differentiate into mature adipocytes, conferring a constant functional plasticity on
adipose tissue [10]. Preadipocytes mature in two steps: differentiation and then hypertro‐
phy. During the early maturation stage, an increased number of mitochondria are required
[11, 12], resulting in small adipocytes, which are highly sensitive to insulin and that secrete
high levels of adiponectin [12]. By contrast, older adipocytes increase in size (hypertrophy),
their functional activities are lost and they become resistant to insulin. These adipocytes also
exhibit decreased numbers of mitochondria with impaired mitochondrial reactive oxygen
species (ROS) generated by the respiratory chain, which could have dual effects on adipo‐
cyte differentiation. New adipocytes form constantly to replace lost adipocytes, to the extent
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that 50 % of adipocytes in the human subcutaneous fat mass are replaced approximately ev‐
ery eight years. Preadipocytes are recruited to become lipid-filled mature adipocytes at the
same rate that adipocytes die, and in this way the fat mass is in constant flux, and adipocyte
number is kept constant. Cellular death of fat cells in white adipose tissue occurs primarily
by necrosis-like cell death, which involves macrophage recruitment and a subsequent in‐
flammatory response. This has been implicated in the metabolic complications of obesity. In‐
creased visceral fat mass leads to IR and a low-grade inflammation status in which many
adipokines and other adipocyte and macrophage factors are involved [13].
Adipose tissue is not homogeneous but rather a tissue with specific regional compartments
with varying roles and metabolic functions [14]. Individually considered, adipose tissue
compartments have stronger associations with physiological and pathological processes
than does total adipose tissue mass [15-17]. The upper-body adipose tissue, including viscer‐
al fat, is involved in fat storage after meals and the release of free fatty acids (FFA) between
meals to feed the liver, muscles and other organs, therefore sparing glucose for the brain.
Visceral fat has a more lipolytic profile than subcutaneous fat. Peripheral lower-body fat, in
the femoro-gluteal region, is mainly used for its storage capacity, thereby buffering excess
fat [7]. The femoro-gluteal fat depot is relatively insensitive to lipolytic stimuli and highly
sensitive to anti-lipolytic stimuli, and may play a protective role by acting as a “sink” for
circulating FFA [18]. This uptake of FFA prevents ectopic fat storage in the liver, skeletal
muscle, and pancreas, which causes IR and beta-cell dysfunction [19]. The excessive lipolytic
capacity of visceral fat (and probably subcutaneous upper-body depots as well) results in a
condition referred as lipotoxicity (see section below on lipotoxicity) [7]. The reasons for the
lower degree of expansibility of visceral adipocytes remain unknown. Visceral adipose tis‐
sue (VAT) differs histologically from subcutaneous adipose tissue (SAT): it has smaller adi‐
pocytes and a larger supply of nerves and vessels; VAT has many of the characteristics of
brown adipose tissue turned into white adipose tissue [20].
3. Lipohypertrophy and lipoatrophy
Adipose tissue can be subject of different influences and undergo different transformations.
SAT has a lower mitochondria content and this contributes to adipocyte apoptosis and
therefore, to more lipoatrophy. VAT, with a higher number of resident macrophages [21]
and more 11βhydroxysteroid dehydrogenase activity than SAT [22], is predisposed to hy‐
pertrophy. Hypertrophied VAT from HIV-infected patients demonstrates mitochondrial
dysfunction but not impairment of adipogenic gene expression in comparison with SAT
[23]. cART can differentially alter fat development depending on the environment and phys‐
iology of the different compartments. In the case of lipoatrophy, because peripheral subcuta‐
neous adipocytes cannot store triglycerides, non-lipoatrophic fat depots such as VAT,
probably buffers the increase in FFA, which worsens lipohypertrophy [8].
Subcutaneous adipocytes seem to be more susceptible to the deleterious effects of protease
inhibitors (PIs) than visceral adipocytes [24]. Accordingly, studies performed on control hu‐
man SAT explants reveal that some PIs increase FFA, interleukin – 6 (IL-6) and TNF-α pro‐
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duction through the activation of the proinflammatory nuclear factor – kB (NFkB) pathway.
This PI-induced deleterious paracrine loop, between adipocytes and macrophages, similar
to the observed in obesity, is not seen in VAT. These data indicate that SAT is more sensitive
to the adverse effects of some PIs than VAT [8].
4. Adipogenesis
Individuals can differ remarkably in body fat distribution and the known differences in FFA
uptake of adipose tissue compartments play a role in this difference. Premenopausal female
SAT takes up more FFAs than male [25] and upper-body SAT takes up FFAs more avidly
than femoral fat in men, but not in women. Gene expression, mRNA transcription of FA
transporters and consequently facilitated FA transport was greater in the upper body in men
and in the femoro-gluteal region in women. This novel FFA disposal pathway may also play
a role in the development or maintenance of body fat distribution. On the other hand, direct
FFA uptake in subcutaneous fat differs from fatty acid uptake from a meal in two respects:
1) direct FFA uptake is more efficient in women than in men and 2) in men there is no pref‐
erential direct FFA uptake in upper-body subcutaneous fat compared with femoral fat in
women. These gender-based differences are consistent with this process as a mechanism to
develop or maintain variations of body fat distribution between men and women, both lean
and obese.The greater direct FFA uptake in abdominal over femoral fat in men could be due
to the greater facilitation of inward fatty acid transport. Contrary to what is generally be‐
lieved, upper-body subcutaneous fat releases ~70 % of systemic FFAs in lean men and wom‐
en, whereas the leg contributes only ~20%; fatty acid uptake from a meal follows a similar
pattern [26]. In non-obese men, the direct uptake/storage of FFAs in upper-body and leg fat
mirrors this regional difference in FFA release, whereas in lean women, direct FFA uptake
was similar in upper-body and femoral adipose tissue. This imbalance between release and
direct reuptake in women could redistribute fatty acids toward leg fat. In obese women, the
total FFA reuptake in leg fat was also significantly greater than in upper-body fat. It may be
that some populations of fat cells, such as the smaller adipocytes, take up but do not actively
release FFAs, whereas larger fat cells briskly release FFAs and do not take up FFAs under
post-absorptive circumstances. In summary, there is a mechanism for adipocyte fatty acid
uptake and storage that has yet to be understood, but which is independent of lipoprotein
lipase and it’s not thought to exist in the post-absorptive state [25].
Macrophage infiltration of the human adipose organ is a well-documented phenomenon
that induces a low-grade chronic inflammation that is associated with IR. This reaction ap‐
pears to be related mainly to macrophage-produced cytokines (TNF-α and IL-6] capable of
interfering with the normal activity of insulin receptors. The greater amount of macrophages
and macrophage-secreted cytokines found in visceral fat is in line with the greater morbidity
associated with these depots. Subcutaneous and visceral adipocytes have cell-autonomous
properties due to inherently different progenitor cells that exhibit a different gene expres‐
sion pattern. Subcutaneous white adipose tissue responds better to the anti-lipolytic effects
of insulin, secretes more adiponectin and less inflammatory cytokines, and is differentially
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affected by molecules involved in signal transduction as well as drugs, compared with vis‐
ceral white adipose tissue [13].
Lipoatrophic adipose tissue is known to be characterized by smaller adipocytes, greater cell
size variation, disruption of cell membranes, and signs of apoptosis as determined by immu‐
nohistochemistry staining, when compared with non-lipodystrophic adipose tissue. There is
a marked difference in gene expression between dorsocervical and abdominal SAT, irrespec‐
tive of the lipodystrophy status, that lies in the expression of homeobox genes involved in
organogenesis and regionalization. Disparate expression of such fundamental regulators of
transcription might ultimately contribute to different patterns of differentiation and affect
the susceptibility of the adipose tissue depot to cART-induced toxicity, perhaps making the
abdominal subcutaneous and femoro-gluteal depot more vulnerable to atrophy [27].
Morphologic alterations in lipoatrophy-prone areas of SAT have been confirmed at the level
of gene expression [9]. Most studies report that these lipoatrophic areas show an abnormally
low expression of the major adipogenic transcription factors peroxisome proliferator-activat‐
ed receptor -γ (PPARγ), sterol-regulatory element binding protein-1 (SREBP-1), and
CCAAT/enhancer-binding protein-α (C/EBPα) [28-30]. Consequently, the expression of adi‐
pogenic differentiation-related genes is also decreased. For example, there is a reduction in
the expression of genes for lipoprotein lipase and for the insulin-sensitive glucose transport‐
er GLUT 4 [28, 29], resulting in impaired fatty acid and glucose uptake, respectively, and
thus leading to a deficit in the lipid-accretion capacity of SAT. Another major alteration de‐
tected, which is probably related to the impaired adipogenic gene expression, is reduced ex‐
pression of the adipokine genes adiponectin and leptin [28, 29]. In addition to impaired
expression of adipogenetic–related genes, adipose tissue from patients with lipodystrophy,
mainly those receiving NRTIs [31, 32] also show a reduction in mitochondrial DNA
(mtDNA) levels. This decrease is associated with complex alterations in mitochondrial func‐
tion, such as reduced expression of mtDNA-encoded transcripts and compensatory up-reg‐
ulation of dysfunctional mitochondrial mass, that likely reduce the endogenous oxidative
capacity of adipose tissue [33]. Moreover, increased oxidative stress and apoptosis have also
been reported in lipoatrophic SAT [34]. Lipoatrophy is also accompanied by a state of chron‐
ic low-level inflammation [35]. High levels of expression of the inflammatory markers, TNF-
α, IL- 6; IL-8 and IL-18 have been reported in SAT from HIV-1-infected lipoatrophic patients
[28, 30, 35-37]. Expression of TNFα and IL-6 mRNA in SAT of lipodystrophic patients corre‐
lates positively with tissue apoptosis and negatively with adipogenic marker expression,
which is consistent with a role for pro-inflammatory cytokines in adipocyte viability and
differentiation [30]. Unlike SAT, VAT did not exhibit impaired expression of adipogenic
marker genes. However, it did show some similar changes in inflammatory markers, such as
induction of TNF-α, whereas others differed from that of SAT, such as, for instance, lack of
monocyte chemoattractant protein -1 (MCP-1] induction. In contrast, mitochondrial dys‐
function in VAT was found to be similar to that in SAT. Therefore, mtDNA depletion and
signs of altered mitochondrial function are common to atrophic (subcutaneous) and hyper‐
trophic (visceral, dorsocervical) depots in HIV-1 lipodystrophy, indicating that mitochondri‐
al impairment cannot explain in a simple manner the final outcome for adipose depots,
either in terms of lipoatrophy or lipohypertrophy [23]. Taken together, these observations
indicate that different responses occurring in subcutaneous and visceral fat depots in lipo‐
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dystrophic patients are likely to be related to intrinsic differences in fat physiology and/or
capacity to react to the same insult. One adipose depot (visceral) enlarges in size and ap‐
proaches its fat storage capacity threshold (as in obesity) merely because another adipose
depot (subcutaneous) cannot [38]. A direct role for HIV-1 infection has been proposed by an‐
alyzing SAT from untreated HIV-1-infected patients (“naïve”) as compared to healthy con‐
trols. Early histological studies did not indicate clear mitochondrial or inflammatory-related
disturbances [39], but subsequent gene expression studies have shown a significant decrease
in the expression of the adipocyte differentiation controller PPARγ and some impairment in
the expression of genes encoding mitochondrial proteins and proteins specifically related to
adipocyte metabolism, including adiponectin and 11β-steroid dehydrogenase type-1, the en‐
zyme responsible for glucocorticoid activation [9, 29]. Some signs of inflammatory response
have also been reported [29]. All these alterations are further enhanced in SAT oflipody‐
strophic patients. Therefore, it appears that HIV-1 infection initiates a first wave of altera‐
tions in adipose tissue that is amplified by cART and ultimately results in lipoatrophy [9].
5. Congenital generalized lipodystrophies
Generalized lipodystrophies are rare disorders that may be congenital or acquired. The ge‐
netic lipodystrophies have been reported in about 1000 patients [2]. The congenital general‐
ized lipodystrophy (CGL) Berardinelli-Seip syndrome (BSCL), is an autosomal recessive
disorder initially reported by Berardinelli [3] and Seip [40] with frequent parental consan‐
guinity [41-44]. It has been proposed that Berardinelli-Seip syndrome could be a Portuguese
disease, later spread by the Portuguese across the world [45].
Patients with CGL are recognized at birth or soon thereafter due to a near-total lack of body
fat and prominent muscularity that causes a severe and striking phenotype (Figure 2A and
2B). Diabetes develops during infancy or most often during the teenage years. Hepatosple‐
nomegaly, umbilical prominence or hernia, acanthosis nigricans, voracious appetite and ac‐
celerated growth can occur. Female patients develop hirsutism, may have clitoromegaly,
oligomenorrhea and polycystic ovaries. Other uncommon manifestations include hypertro‐
phic cardiomyopathy, mild mental retardation, and focal lytic lesions in the appendicular
bones after puberty [41, 42]. Diabetes and its complications, hyperlipidemia and recurrent
attacks of acute pancreatitis, hepatic steatosis and occasionally cirrhosis are the causes of
morbidity and mortality [2].
At least 4 molecularly distinct forms of congenital lipodystrophy have been defined, with
the mutations of the enzyme acyltransferase 1-acylglycerol-3-phosphate O- acyltransferase 2
(AGPAT2) or (BSCL1- locus 1) and Berardinelli-Seip (BSCL2 - locus 2) being both responsi‐
ble for 95 % of gene mutations. AGPAT2 has been mapped in chromosomes 9q34. AGPATs
are critical enzymes involved in the biosynthesis of triglycerides and phospholipids from
glycerol-3-phosphate. They catalyze acylation of fatty acids at the sn-2 position of glycerol
moiety and convert lysophosphatidic acid to phosphatidic acid [2, 46]. AGPAT2 is highly ex‐
pressed in the adipose tissue, and its deficiency may cause lipodystrophy by limiting trigly‐
ceride or phospholipid biosynthesis [47].
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Figure 1. A: Two sisters with Berardinelli-Seip syndrome B: Women with Berardinelli-Seip syndrome
Type 2 CGL is due to BSCL2 gene mutations. This gene is located in chromosome11q13 and
encodes a protein called seipin [48]. Seipin appears to play a role in lipid droplet formation
and may also be involved in adipocyte differentiation [49-51].
Patients with BSCL2 mutations have the most severe variety of CGL and are born without
any body fat [2]. Two other genes were identified for CGL: caveolin 1 (CAV1) [52] and poly‐
merase I and transcript release factor (PTRF) [53]. Caveolin 1 is the main component of cav‐
eolae, specialized microdomains seen in abundance on adipocyte membranes [54]. It binds
fatty acids and translocates them to lipid droplets. PTRF (also known as cavin) is involved in
biogenesis of caveolae and regulates expression of caveolins 1 and 3 [53].
6. Mortality in generalized lipodystrophies
Patients with generalized lipodystrophies are predisposed to develop acute pancreatitis, cir‐
rhosis, endstage diabetic renal disease requiring transplantation, and blindness due to diabet‐
ic retinopathy. Many patients with FPL die of coronary heart disease or cardiomyopathy and
rhythm disturbances [55-57]. Sudden death has been reported during childhood in CGL, type
4, likely due to arrhythmias [58]. Patients with HIV-lipodystrophy are predisposed to develop‐
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ing coronary heart disease [59]. Patients with congenital Berardinelli-Seip lipodystrophy fre‐
quently develop hypertrophic cardiomyopathy that can lead to death from cardiac failure [41].
In individuals with BSCL, ventricular dysfunction and hypertrophic cardiomyopathy are of‐
ten observed. In cardiac biopsies performed in eight individuals with BSCL, the presence of
subendocardial fibrosis and an abnormal architecture in the left ventricular lumen was ob‐
served [60, 61]. Hypertrophic cardiomyopathy in BSCL patients has been correlated with high
plasmatic insulin levels, which activate the type 1 insulin-like growth receptors, present in
large quantities in the myocardial tissue, that stimulate cell growth [62, 63]. In addition, the
presence of IR and hypertriglyceridemia in individuals with BSCL may predispose them to
premature  atherosclerosis.  Individuals  who have  mutations  on chromosome 11  (BSCL2)
seemed to present more severe symptoms than those who had mutations in BSCL1, with a high
incidence of premature deaths. Cardiomyopathy was three times more frequent in those with
BSCL2 mutations than in individuals with alterations in BSCL1 [42].
7. Mandibuloacral Dysplasia (MAD)-associated lipodystrophy
MAD is characterized by skeletal abnormalities such as mandibular and clavicular hypoplasia
and acroosteolysis [64], progeroid manifestations, partial or generalized lipodystrophy and
metabolic complications, among other clinical features [65, 66]. Patients with MAD harbor mu‐
tations in lamin A/C (LMNA) or zinc metalloproteinase (ZMPSTE24) [67, 68]. ZMPSTE24 is in‐
volved in post-translational proteolytic processing of prelamin A to mature laminA [2].
8. Autoinflammatory syndromes
A syndrome of joint contractures, muscle atrophy, microcytic anemia, and panniculitis-in‐
duced (JMP) lipodystrophy was reported by Garg in three patients, belonging to two pedi‐
grees, who were from Portugal and Mexico [69]. Three other patients have been reported from
Japan [70, 71]. Mutations in PSMB8 may trigger an autoinflammatory response resulting in in‐
filtration of adipose tissue with lymphocytes and other immune cells and adipocytes [2]. The
other autoinflammatory syndrome is the chronic atypical neutrophilic dermatosis with lipo‐
dystrophy and elevated temperature (CANDLE) syndrome. The mode of inheritance seems to
be autosomal recessive, but the molecular basis remains unknown [2, 72, 73].
9. Familial Partial Lipodystrophy(FPL)
FPL is characterized by the onset of fat loss from the limbs and other regions of the body, usu‐
ally during childhood, adolescence or adulthood. Many regions of the body, such as the face,
neck, and intra-abdominal region are spared, and patients accumulate excess body fat in the
non-lipodystrophic regions [74-76]. Metabolic complications, acanthosis nigricans, oligoame‐
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norrhea, hirsutism, polycystic ovarian syndrome, mild to moderate myopathy, cardiomyop‐
athy, and conduction system abnormalities indicative of multisystem dystrophy can occur [2,
55, 56, 77]. The identification of the first gene for FPL, Dunnigan variety, i.e. LMNA, on chro‐
mosome 1q21-22 [2, 78-81], an integral component of nuclear lamin, was made in 1998. There‐
after, four other genes were identified: PPARγ [82-84], a key transcription factor involved in
adipocyte differentiation;  v-AKT murine thymoma oncogene homolog 2 (AKT2) [85],  in‐
volved in downstream insulin signaling; and cell death-inducing DNA fragmentation factor a-
like  effector  c  (CIDEC) [86]  and perilipin 1  (PLIN1)  [87],  both involved in lipid droplet
formation [2, 88]. Adipocyte loss is due to premature cell death resulting from disruption of the
nuclear envelope [87, 89]. Defective adipocyte differentiation seems to be the cause of the lipo‐
dystrophy of PPARγ and AKT2 mutations. Fibrosis of adipose tissue with small adipocytes is
responsible for the lipodystrophy of PLIN1 mutations [2, 87].
There are other rare genetic syndromes whose molecular basis remains unknown, namely
atypical progeroid syndrome [90], Hutchinson-Gilford progeria syndrome [91], SHORT-as‐
sociated lipodystrophy [92], and Wiedemann-Rautenstrauch syndrome [93].
Patients with FPL syndromes display mixed lipodystrophy with subcutaneous lipoatrophy
and central fat accumulation. Those with FPLD2 also have an increased amount of fat in the
cervico-facial area compared to patients without these mutations. Therefore, a single protein
mutation leads to two opposing fat localization phenotypes [8]. Importantly, mutations in
LMNA are also responsible for metabolic laminopathies resembling the metabolic syndrome
(MS) and Hutchinson-Gilford progeria, a severe syndrome of premature aging [94]. Prelamin
A is implicated in increased oxidative stress and in the occurrence of cellular senescence [8].
10. Acquired lipodystrophies
10.1. Acquired Generalized Lipodystrophy(AGL) – Lawrence syndrome
The onset of subcutaneous fat loss in patients with AGL usually occurs during childhood
[95]. The pattern and extent of fat loss is quite variable and most patients have generalized
loss of fat, but a few of them have areas such as intra-abdominal and bone marrow fat
spared. AGL patients are highly likely to develop severe hepatic steatosis and fibrosis, dia‐
betes, and hypertriglyceridemia [2]. The pathogenesis of fat loss remains unknown. Panni‐
culitis may precede loss of fat. Lipodystrophy can be associated with autoimmune diseases
such as juvenile dermatomyositis [95]. Chronic hepatitis with autoimmune features and low
serum complement 4 levels, suggesting involvement of the classical complement pathway in
the pathogenesis of fat loss, has been reported [96].
10.2. Acquired partial lipodystrophy–Barraquer-Simons syndrome
Fat loss occurs gradually in a symmetric fashion, first affecting the face and then spreading
downward. Most patients lose fat from the face, neck, upper extremities, and trunk, and
subcutaneous fat from the lower abdomen and legs is spared. Many patients accumulate ex‐
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cess subcutaneous fat in the hips and legs. Metabolic complications are rare. Misra et al sug‐
gest that the fat loss involves autoimmune-mediated destruction of adipocytes because the
patients have low serum levels of complement 3 and complement 3-nephritic factor, which
blocks degradation of the enzyme C3 convertase [95]. It is possible that the C3-nephritic fac‐
tor induces lysis of adipocytes expressing factor D [97].
10.3. Localized lipodystrophy
Localized lipodystrophies present focal loss of subcutaneous fat, usually causing one or
more dimples, and in general occurs due to subcutaneous injection of various drugs (Figure
4), panniculitis, pressure, and other mechanisms [98].
Figure 2. Patient with lipohypertrophy related to subcutaneous administration of pegvisomant.
10.4. Lipodystrophy associated with HIV-infection
The impressive progress resulting from the discovery of drugs able to control HIV infection
on a long-term basis, has offered most patients a prolonged lifespan, possibly as long as that
observed in non-infected subjects [7]. Suppression of viral replication has become a treat‐
ment goal that can be reached with the use ofcART. After the introduction of protease inhib‐
itors (PIs) in 1996, as a component of highly active antiretroviral therapy, the morbidity and
mortality associated with HIV has dramatically been reduced [99]. However, patients devel‐
op a syndrome of fat redistribution with peripheral fat loss (face, upper limbs and femoro-
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gluteal) and visceral fat accumulation, generally associated with metabolic abnormalities [4,
100-103] and increased risk of CV diseases [104, 105], similar to what occurs in congenital
lipodystrophies [4, 59]. Lipohypertrophy usually represents a central visceral fat accumula‐
tion in the abdomen and trunk, but can also be found in breasts (in women), dorsocervical
region (“buffalo hump”), double chin, lipomas, and within the muscle and liver [59, 106].
Lipoatrophy and lipohypertrophy are frequently associated (mixed form), but they also can
occur independently of each other [59]. This HIV-associated lipodystrophy has been pro‐
posed to be a age-related fat redistribution condition that could amplify age-related co-mor‐
bidities and lead to their earlier occurrence [8]. Also, hyperlactenemia and bone
demineralization can occur [107, 108].
Owing to a lack of a consensus on the definition of lipodystrophy and lipodystrophy syn‐
drome in HIV-infected patients, its exact prevalence is not known [6]. In the early 2000s, about
half of HIV-infected patients undergoing cART were diagnosed as lipodystrophic (20-80%)
[109]. Abnormalities in peripheral and central fat masses are clinically evident in 20-35 % of pa‐
tients after approximately 12-24 months of cART [59, 107, 110, 111]. With the new anti-retrovi‐
ral agents, the probability of developing lipoatrophy has decreased in western countries as the
pattern of cART prescription has significantly changed [112]. In the study of Nguyen, lipodys‐
trophy has become less frequent since 2003 [112]. Two widely used thymidine analogs from
the first class of ART, stavudine and zidovudine, are responsible for lipoatrophy and now they
have been replaced by a new generation of potent NRTIs. Although metabolic toxicity of boost‐
ed PIs is far less than of first-generation protease inhibitors (PIs), they are still considered re‐
sponsible for increased CV risk. The new classes of ART, fusion inhibitors (F20), integrase
inhibitors (raltegravir) or entry inhibitors (anti-CCR5, maraviroc) have not yet been shown to
alter metabolic parameters or fat distribution [8, 112-117].
HIV-infected patients can have 4 different phenotypes of body fat composition: no lipodys‐
trophy, isolated peripheral lipoatrophy, isolated central fat accumulation and a mixed form
of lipodystrophy (or redistribution syndrome) [100]. About 50% of patients with HIV-associ‐
ated lipodystrophy display mixed forms, with the loss of limb fat and marked expansion of
VAT [113]. The high frequency of this association suggests that these two opposite pheno‐
types could be, at least in part, causally related [8]. Also, HIV patients may have a picture
similar to partial lipodystrophy patients with peripheral fat atrophy and hypertrophied cen‐
tral fat depots. Thus, there are similarities between HIV lipodystrophy and genetic forms.
11. HIV-lipodystrophy and related factors
There is a possible role of the virus contribution for lipodystrophy i.e. the HIV or hepatitis in‐
fection affects fat tissue before any ART. Monocytes are relatively resistant to HIV infection,
but differentiated macrophages are highly susceptible and tissue macrophages have been
found to harbor HIV-1 [118]. Infected macrophages release pro-inflammatory cytokines. Sys‐
temic inflammation associated with HIV infection might promote monocyte migration across
the vascular endothelium, leading to an increased number of activated macrophages in fat
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[118]. Several studies reported that the severity of HIV infection is associated with an in‐
creased prevalence of lipodystrophy [59, 119], probably as a consequence of persistent HIV-in‐
fected macrophages in adipose tissue, which could enhance local inflammation.
ART-naïve HIV-positive patients have increased TNF-α expression compared with uninfect‐
ed controls [29], which is consistent with increased inflammation. TNF-α alters adipocyte
function and differentiation, in part through the inhibition of PPARγ expression [120]. In‐
fected macrophages might also release viral proteins (such as Vpr and Nef) that can impact
on adjacent adipocytes and lead to decreased PPARγ activity and inhibition of adipogenesis
[121, 122]. Although lipodystrophy is uncommon in ART-naïve patients [113], the HIV infec‐
tion of macrophages could itself result in low-grade fat inflammation and lead to the release
of viral proteins that affect neighboring adipocytes and decrease their differentiation.
The development of lipodystrophy and metabolic toxicities is partially related to the indi‐
vidual drugs included in cART regimens, associated with other risk factors [123] such as
gender and pre-HIV-infection body composition, disease-specific factors such as the nadir
levels of CD4+ lymphocytes and the duration of HIV infection [110, 123, 124]. The most sig‐
nificant risk factors associated with lipoatrophy are exposure to and duration of nucleoside
thymidine analogues (most commonly stavudine), age, severity of disease markers (CD4
lymphocyte count and plasma HIV viral load), therapy duration, and belonging to the Cau‐
casian race. On the other hand, the most common statistically significant risk factors for lipo‐
hypertrophy are therapy duration, PI administration, markers of disease severity, and age.
We cannot forget that along the years, patients have done multiple regimes and combina‐
tions of antiretroviral drugs, which makes it difficult to identify different risks with different
drugs, and studies therefore report conflicting results [6].
Figure 3. FFA uptake by gender (SAT - abdominal subcutaneous adipose tissue; VAT – visceral adipose tissue; FFA –
free fat acids)
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12. Protease inhibitors
PIs affect multiple metabolic pathways and are associated with lipohypertrophy, lipoatrophy,
atherogenic dyslipidemia and IR, [125, 126]. Studies in-vitro reported that PIs are able to alter a
number of adipocyte functions, including differentiation, expression of transcriptase factors
involved in adipogenesis, cell survival, cytokine production, mitochondrial function and IR
[127]. PIs may cause lipodystrophy by inhibiting ZMPSTE24, resulting in accumulation of tox‐
ic farnesylated prelamin A [128], increased oxidative stress and altered adipokine and cyto‐
kine production [89, 127, 129]. The adverse effect of PIs could also result from the induction of
endoplasmic reticulum stress or the inhibition of the proteasome [130, 131].
Different PIs might affect key intranuclear genes, causing reduction in levels of RNA encod‐
ing SREBP-1, which changes the expression of PPAR γ [28]. The levels reduction of intranu‐
clear SREBP-1 leads to a decreased adipocyte differentiation and an altered release of
adipocytokines [132]. PIs can inhibit lipogenesis and stimulate lipolysis [28, 132-135], and
may induce IR by inhibiting glucose transporter 4 expression (GLUT4) [136].
13. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
NRTIs are analogs that inhibit the viral reverse transcriptase enzyme. The thymidine NRTIs
(zidovudine, stavudine and didanosine) cause mitochondrial toxicity by mitochondrial DNA
polymerase inhibition and by causing DNA mitochondrial mutations [31, 137, 138]. These dis‐
turbances result in apoptosis of peripheral adipocytes and lead to lipoatrophy [31]. NRTIs are
also associated with fat hypertrophy in visceral depots [113, 139, 140]. Nucleoside analogues
may inhibit adipogenesis and adipocyte differentiation, promote lipolysis, and exert synergis‐
tic toxic effects when associated to PIs [31, 141-143]. Moreover, NRTIs promote lipolysis and
the subsequent efflux of non-esterified fatty acids from adipose tissue [142, 144].
14. Mitochondrial toxicity and fat redistribution
In western countries, long-term HIV-infected patients present several age-related comorbid‐
ities earlier than the general population [145], and display signs of premature aging [8]. New
hypotheses were recently suggested about the pathophysiology of fat redistribution, pro‐
posing that mitochondrial toxicity was involved in lipoatrophy and in fat hypertrophy. HIV-
associated lipodystrophy could be an age-related fat redistribution that could amplify age-
related comorbidities and their earlier occurrence [8]. Mitochondria play an important role
in adipocyte differentiation and function. At physiological low levels, ROS could act as sec‐
ondary messengers to activate adipogenesis and lipogenesis, resulting in increased adipo‐
cyte number and size. In hepatic cells, oxidative stress activates the transcription factor
SREBP1c, which is highly expressed in adipocytes and increases lipogenesis and lipid accu‐
mulation [146]. At higher levels, ROS could inhibit differentiation [8].
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Figure 4. Acquired partial lipodystrophy - Barraquer-Simons syndrome
Excessive VAT releases increased visceral adipocyte-FFAs, adipokines and cytokines. In‐
deed, activated macrophages, which have an M1 proinflammatory phenotype, invade ex‐
panded adipose tissue; upon invasion, their production of proinflammatory cytokines and
chemokines increases. This could lead to the decreased secretion of adiponectin by adipo‐
cytes in response to TNF-α [36]. Increased abdominal fat lipolysis increases ectopic fat depo‐
sition within tissues (liver, skeletal muscle and heart). Subsequently, these derivatives
overwhelm mitochondrial oxidative capacity and activate stress kinases, leading to IR. This
situation, known as lipotoxicity, associates ectopic depots of triglycerides in non-adipose tis‐
sues that buffer excess fatty acid derivatives [147]. Moreover, a paracrine loop is present be‐
tween adipocytes and macrophages; macrophage-secreted cytokines (TNF-α and IL-6]
activate the NFkB pathway in adipocytes, resulting in increased IL-6 and FFA production.
Saturated FFA can, in turn, activate the Toll-like receptor-4 (TLR-4) on macrophages and
adipocytes, thereby increasing the proinflammatory loop. This paracrine loop has been re‐
ported in obesity as a result of macrophages infiltrating fat [148].
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15. Cortisol and fat redistribution
Patients with hypercortisolism also have an acquired form of lipodystrophy [1], character‐
ized by fat hypertrophy in the upper body with increased VAT and decreased limb fat. Cor‐
tisol can activate adipocyte differentiation and hypertrophy, mainly in visceral fat depots,
because of the higher expression of glucocorticoid receptors (GR-α) and the 11β-hydroxyste‐
roid dehydrogenase type 1 (11β-HSD-1) that transforms inactive cortisone into active corti‐
sol in adipocytes from central depots [22]. In addition, cortisol induces IR and increases
lipolysis in adipocytes [22]. It has been hypothesized that glucocorticoid activation is in‐
volved in cART-linked central fat hypertrophy [8]. Higher ratios of urinary cortisol:cortisone
metabolites and higher subcutaneous 11β-HSD-1 expression are observed in patients with
severe lipodystrophy compared with those without [149]. In cART-naïve patients, 11β-
HSD-1 expression increases in both abdominal and thigh SAT after 12 months of ART, but
only in patients with lipohypertrophy or without lipoatrophy [150]. Because TNF-α expres‐
sion in fat is related to that of 11β-HSD-1 [149], inflammation is linked to glucocorticoid acti‐
vation [8]. TNF-α activates 11-β-hydroxysteroid dehydrogenase (HSD)-type 1, and this
enzyme’s activity is higher in visceral fat compared with subcutaneous fat. Visceral fat is
able to locally produce cortisol, which could act inside the adipocytes and increase lipid ac‐
cumulation [151]. Other hormones, such as growth hormone and testosterone, can modulate
the activity of 11β-HSD-1. It is interesting to note that HIV-infected patients with lipodystro‐
phy often present with a relative decrease in growth hormone [152] and testosterone levels.
Moreover, when patients with visceral fat hypertrophy are treated with growth hormone, a
reduced amount of visceral fat is reported, together with improved metabolic status [153].
16. Aging
In the general population, age is associated with central fat redistribution, mitochondrial im‐
pairment and increased levels of pro-inflammatory cytokines [154]. Aging adipocytes re‐
lease more pro-inflammatory cytokines than young ones [155]. Aging is physiologically
associated with fat redistribution, oxidative stress and low-grade inflammation. In the gen‐
eral population, the interaction between the proinflammatory state and genetic background
potentially triggers the onset of age-related inflammatory diseases such as atherosclerosis,
sarcopenia and frailty. Decreased immune response leading to immunosenescence is also
probably involved in early aging [8, 156]. Aging and some cARTs result in mitochondrial
dysfunction and oxidative stress, which lead to cellular senescence. Moreover, some PIs in‐
duce the accumulation of the pro-senescent protein prelaminA [8].
17. Genetic factors and HIV-lipodystrophy
A role for genetics is also probable in HIV-lipodystrophy. TNF-α gene promoter polymor‐
phism is associated with lipodystrophy, but this association has not been confirmed in larg‐
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er studies [157]. Interestingly, stavudine-induced lipoatrophy is linked to the HLA-
B100*4001 allele, which is located in close proximity to the TNF-α gene; this observation
further supports the theory that there is a role for inflammation in lipoatrophy [158]. Apo
C3-455 also plays a role in lipoatrophy, and two variants of the adipogenic β2 receptor
seems to be involved in fat accumulation, whereas PPARγ variants are not involved [159].
The toxicity of ART also depends on a patient’s metabolism, in part genetically determined.
18. Role of inflammation
Even if infectivity of adipocytes by HIV has been contested, the ability of the virus to modify
adipocyte phenotype has been shown in some studies [160, 161]. Moreover, macrophages
and dendritic cells present in lipodystrophic adipose tissue could be infected, which could
modify their characteristics [7]. Macrophage infiltration is observed in adipose tissue from
patients with HIV-related lipodystrophy together with decreased adipokine and increased
pro-inflammatory cytokine production [162]. Some anti-retrovirals increase oxidative stress
and generation of reactive species, which results in decreased production of adiponectin and
leptin by adipocytes and increased production of pro-inflammatory cytokines [7].
Figure 5. Patient with mixed lipodystrophy (absence of subcutaneous peripheral fat in arms, legs and face and in‐
creased abdominal fat mass)
Current Perspectives in HIV Infection276
19. Lipotoxicity
Lipotoxicity is a possible explanation for the development of metabolic syndrome (MS) and
diabetes in multiple pathological situations, from obesity to lipodystrophies of distinct ori‐
gin. According to the lipotoxicity theory, excess availability of fatty acids or a limited capaci‐
ty to metabolize them in organs and tissues elicits most of the alterations that are
characteristic of MS, especially IR. The toxicity of fatty acids toward β-cells may lead to al‐
tered insulin production. Actually, high FA levels can induce a reduction in GLUT2 on β cell
surfaces and induce a decrease in insulin secretion [19]. Increased availability and, ultimate‐
ly, increased accumulation of fat into skeletal muscle tends to promote IR; and fatty acid lev‐
els in liver that exceed the capacity of this organ to oxidize or export them, lead to the
increased accumulation of fat that is often associated with MS. All of these events could re‐
sult from alterations in fat metabolism or excess intake of fat-enriched nutrients, but they
could also arise as a result of intrinsic alterations in the capacity of adipose tissue to store
and thereby buffer the excessive accumulation of fatty acids in other tissues and organs
[163]. One hypothesis consistent with the appearance of MS in ART-associated lipodystro‐
phy syndrome is lipotoxicity resulting from limitations in the capacity of subcutaneous fat
to store the appropriate amounts of fat and the subsequent diversion of fatty acids to ectopic
sites [164]. Several arguments in support of lipotoxicity as a major contributor to MS in dis‐
tinct human pathologies come from the paradoxically common metabolic alterations found
in the obesity and in lipodystrophies of genetic origin. According to the lipotoxicity theory,
the fat stored in adipose tissue is biologically inert and the observed metabolic alterations
are primarily caused by the increased exposure of cells to non-esterified fatty acid. Thus, in
obese patients, it is not the amount of fat stored in adipose tissue that elicits metabolic dys‐
functions, but rather the balance between the availability of those fatty acids to tissues and
organs and the capacity of the organs to eliminate them through triglyceride storage in adi‐
pose tissue, or oxidation [165]. A complementary concept is the idea that there is a threshold
for adipose tissue expansibility; once it’s reached, as it occurs in obese individuals, appropri‐
ate storage of fatty acids inside adipocytes in their inert and esterified form is impaired, de‐
termining the extent of lipotoxicity [164]. Either a total or partial lack of adipose tissue
storage capacity causes an increase in circulating lipid levels and is associated with ectopic
lipid accumulation in non-fat tissues such as liver, skeletal muscle and pancreas. These alter‐
ations lead to non-alcoholic fatty liver diseases, hepatic and muscle IR and development of
type 2 diabetes. Adipokine deficiency further contributes to metabolic alterations (e.g. hy‐
perphagia) owing to an associated leptin deficiency, which also contributes to positive ener‐
gy balance and potential lipotoxicity through increased fat intake [94].
20. Insulin resistance
IR occurs in about one-third of patients on certain PI-based regimens, although the thymi‐
dine NRTIs have also been associated [166]. Asymptomatic type 2 diabetes mellitus is diag‐
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nosed in 5-10 % of patients [126]. The new-generation PIs appear to have a milder IR effect
and the prevalence of diabetes is lower than described in the early 2000s. Its prevalence,
however, remains higher than in the general population at the same age. In particular, pa‐
tients with severe lipodystrophy are more prone to develop IR [7]. The pathogenesis of glu‐
cose metabolism disorders is still unclear and, although a direct effect of potent
antiretroviral combinations is certainly involved, it is likely that multiple factors play a role,
including genetic predisposition, cytokine and hormonal alterations, changes in the immune
system, non-antiretroviral drug-induced toxic effects, opportunistic diseases, and perhaps
the HIV infection itself [167]. Risk factors for the development of IR in HIV-positive popula‐
tion include duration of ART, PI treatment, concurrent fat redistribution syndrome, dyslipi‐
demia, increasing age, hepatitis C virus co-infection, as well as pharmacological treatment
with pentamidine or megestrol acetate [100, 167-169].
PIs (including indinavir, amprenavir, nelfinavir, and ritonavir) have been shown to induce
IR in vitro by reducing glucose transport mediated by the glucose transporter 4, a receptor
involved in glucose uptake [136]. The deleterious impact of some PIs on adipocytes through
the inhibition of GLUT4 transporters was directly demonstrated in healthy controls, after
given these molecules for a few weeks [169-171]. Several PIs can interfere with nuclear tran‐
scription factors, leading to decreased adiponectin levels, which also leads to IR [123]. Some
PIs might also cause mitochondrial toxicity [172]. Additionally, the increase in FFA levels as‐
sociated with PIs, as well as with fat redistribution, might also have a role in the develop‐
ment of IR (see lipotoxicity) [173].
21. Dyslipidemia
A number of HIV-infected patients present dyslipidemia, increased cholesterol, low-density
lipoprotein (LDL)-cholesterol and triglycerides together with decreased HDL. This profile
has been associated with the presence of a MS, resulting from an increased visceral fat
amount with IR [7].
In patients receiving cART, the prevalence of hyperlipidemia ranges from 28 to 80% in dif‐
ferent studies [167, 174], and it includes hypertriglyceridemia in the majority of cases [123].
Dyslipidemia is frequently, but not always, associated with fat redistribution syndrome: al‐
though lipid and glucose metabolism alterations are more common in patients with body-fat
abnormalities, they are also observed in those without these morphological changes [167].
Several pathogenetic mechanisms have been proposed to explain cART-associated hyperli‐
pidemia, which seems to result from a complex and multifactorial pathologic process: possi‐
bly HIV infection itself, leading in some cases to permanent low grade inflammation with
abnormal levels of some pro-inflammatory cytokines; lipodystrophy itself, as in the genetic
forms, with decreased lower-body fat depots and increased visceral fat; and antiretroviral
molecules (PIs, NNRTIs and some NRTIs) [7].
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Figure 6. Genetic and adquiredlipodystrophies (CGL – congenital generalized lipodystrophy; BSS – Berardinelli-Seip
syndrome; cART- combined antiretroviral therapy; NRTI – nucleoside and nucleotide reverse transcriptase inhibitors; PI
- protease inhibitors; FPL- familiar partial lipodystrophy; MADL- mandibuloacral dysplasia associated lipodystrophy;
adapted from Agarwal&Garg. Ann Rev Genomics Human Genet 2006; 7: 175-199]
Various mechanisms involved in ART-related dyslipidemia have been described: reduction
in the catabolism of VLDL, increased VLDL production, impaired catabolism of FFA, in‐
creased liver triglyceride synthesis, increased secretion of apolipoprotein B-containing lipo‐
proteins, reduced expression of LDL receptors, reduced degradation of SREBP, and
reduction in FXR (farnesoid X receptor) [175]. The first hypothesized mechanism is based
upon the structural similarity between the catalytic region of HIV-1 protease and two hu‐
man proteins involved in lipid metabolism: the cytoplasmic retinoic acid-binding protein
type 1 (CRABP-1) and the low-density lipoprotein-receptor-related protein (LRP). PIs proba‐
bly bind to CRABP-1 and erroneously inhibit the formation of cis-9-retinoic acid, leading to
increased apoptosis of peripheral adipocytes, decreased lipid storage and increased lipid re‐
lease into the bloodstream. Similarly, PIs may inhibit the normal functioning of LRP and in‐
terfere with fatty acid storage in the adipocytes [167, 176]. Furthermore, data from in vitro
and in vivo studies suggest that PIs may prevent proteasomal degradation of nascent apoli‐
poprotein B, a key protein component of circulating triglycerides, leading to increased pro‐
duction of VLDL particles. An upregulation of metabolic pathways leading to an excessive
production of VLDL can also be caused by the PI-induced intra-hepatocyte accumulation of
nuclear transcription factors involved in the metabolism of apolipoprotein B, such as SRBPs.
In addition, the levels of lipoprotein particles containing apolipoprotein C-III and apolipo‐
protein E are increased in PI-treated patients [176-179].
22. Metabolic syndrome
In the general population, MS is described as an association of increased upper-body fat,
particularly in the visceral area, with IR responsible for and revealed by metabolic altera‐
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tions, including increased LDL, decreased HDL, increased triglycerides, increased glycemia
or diabetes and increased blood pressure [180-182]. All these parameters constitute a con‐
stellation of major CV risk factors [180]. This situation also includes low-grade inflammation
and a prothrombotic state [7].
The pathophysiology of MS is complex – genetic factors, aging and weight gain associated
with sedentariness and food habits constitute major risk factors. Also, decreased mitochon‐
drial function related to aging [183] and an age-related redistribution of fat towards the cen‐
tral, visceral areas are involved, leading to IR and metabolic abnormalities [7].
The components of the HIV lipodystrophy syndrome(s) bear a striking resemblance to those
of MS [123]. Both can present hyperinsulinemia, glucose intolerance, central or abdominal
obesity, hypertension, atherogenic lipid profile, hyperuricemia, prothromboticand proin‐
flammatory states [123].
Liver lesions of nonalcoholic steatohepatitis (or NASH) are a complication of MS, with a
possible evolution towards severe liver complications such as cirrhosis. HIV-infected pa‐
tients, with IR in the context of a severe lipodystrophy, present an increased risk of liver le‐
sions [184]. Moreover, as HCV infection has been associated with steatosis and hepatic IR
resulting from viral or metabolic effects, HCV co-infection could aggravate the metabolic
and liver status of HIV-infected patients [185]. HIV-infected patients with MS are more like‐
ly to have higher values of carotid intima-media thickness (cIMT) and detectable coronary
artery calcium score [186].
23. Clinical sequelae associated with HIV and HIV-lipodystrophy
Different studies suggest that the CV risk is increased among HIV-infected patients on cART
and the responsible mechanisms are complex: in addition to the direct effect of the virus on
the vasculature, the toxicity of antiretroviral drugs and the set of metabolic alterations ag‐
gregated in the MS are involved [187]. Whether the increased CV risk is due to HIV infection
itself, to ART, or to a synergistic interaction between these factors, remains to be established
[167]. HIV infection itself may increase CV risk. The HIV surface glycoprotein gp120 can
stimulate endothelial cell production of tissue factor, an early step in the development of
atherosclerosis [188]. Both HIV infection and ART promote atherosclerosis and its clinical
manifestations through inflammatory mechanisms involving endothelial cells, either direct‐
ly or indirectly, and also by inducing lipid alterations [189, 190].
Furthermore, some data suggest that endothelial dysfunction, impaired fibrinolysis, and ex‐
cess inflammation are more common in HIV-positive patients than in general population,
which may contribute to an increased CV risk [191]. At the same time, cIMT and coronary
calcification assessments suggest increased incidence of atherosclerotic disease and prema‐
ture occurrence of arterial atherosclerotic lesions among HIV-infected individuals [192]. Sur‐
rogate markers of atherosclerosis, including abnormal cIMT [193, 194], altered endothelial
reactivity [195], abnormal coronary calcium scores [196], higher than expected C-reactive
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protein levels and abnormal proinflammatory and prothrombotic indices [197], all suggest a
state of increased atherosclerotic risk [123].
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Figure 7. The relationship between HIV infection, lipodystrophy, ART, insulin resistance, adipokines, metabolic altera‐
tions, metabolic syndrome and cardiovascular disease risk
Endothelial cells have been shown to be variably permissive for HIV infection. The HIV virus
itself is able to penetrate coronary artery and brain microvascular endothelial cell membranes
and to initiate inflammatory and biochemical intracellular reactions [198, 199]. The activation
of endothelium induced by either HIV infection itself or by a leukocyte-mediated inflammato‐
ry cascade triggered by the same virus leads to an increased expression of endothelial cellular
adhesion molecules, such as intercellular adhesion molecule 1 (ICAM-1), vascular adhesion
molecule 1 (VCAM-1], E-selectin, P-selectin, thrombomodulin, tissue plasminogen activator
(tPA), and PAI-1. A significant association between increasing serum concentrations of adhe‐
sion molecules and risk of future myocardial infarction has been shown in apparently healthy
men and women, and these molecules are now considered as soluble biomarkers of endothe‐
lial inflammation and early atherosclerosis [200, 201]. Increased serum levels of ICAM-1,
VCAM-1, E-selectin, and thrombomodulin were demonstrated in patients with advanced HIV
infection and opportunistic diseases. A correlation between ICAM-1 concentrations and the
progression of disease as well as the reduction of CD4 lymphocyte count was also reported. If
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circulating adhesion molecules indicate vascular endothelium injury, it seems clear that endo‐
thelium injury is associated with the progression and severity of HIV disease [202]. cART
should reduce the endothelial damage by controlling HIV infection, but it would also contrib‐
ute to stimulating endothelial activation by deranging both lipid and glucose metabolism
[167]. Some PIs, as ritonavir and indinavir are able to directly cause endothelial dysfunction,
with mitochondrial DNA damage and cell death, independently of lipid profile [203]. cART
may promote atherosclerosis both by direct effects on endothelial cells and by indirect effects
associated with metabolic disturbances [167].
Elevated serum levels of PAI-1, tPA, and CRP, as well as reduced serum levels of adiponec‐
tin could be considered biochemical markers of endothelial dysfunction, metabolic altera‐
tions, and CV risk in HIV-infected patients [192]. Some authors suggested that the
pathogenetic mechanism responsible for carotid lesions associated with HIV infection may
be more similar to an inflammatory process than to the classical atherogenesis [204, 205].
Some retrospective and prospective studies have shown that the incidence of myocardial in‐
farction in HIV-positive subjects treated with ART tends to be higher than in the general
population, particularly in those receiving a PI-based treatment [206]. However, reports
from large observational studies demonstrate that there is still considerable controversy re‐
garding the association of cART, particularly PI-based combinations, with increased inci‐
dence of coronary heart disease risk [167].
Moreover, prospective studies involving large cohorts of HIV-infected patients have docu‐
mented an increased incidence of myocardial infarction and cerebrovascular diseases in as‐
sociation with a prolonged exposure to cART. However, the absolute risk of CV events
remains low, and should be balanced against the remarkable benefits ofcART in terms of im‐
provement in immune function and related morbidity and mortality [167].
In other words, incidence of CV disease in successfully cART-treated HIV-infected patients
is low. However, the risk of CV disease is increased compared with that of uninfected peo‐
ple. This fact is due in great part to a higher prevalence of underlying traditional CV risk
factors that are mostly host dependent. HIV may additionally contribute through immune
activation, inflammation, and immunodeficiency. In a more modest way than HIV infection,
the type of ART may also contribute, mainly through the impact on metabolic and body fat
parameters, and possibly through other factors that are currently unclear. From the CV per‐
spective, the benefits of ART outweigh any potential risk [207, 208].
24. Conclusions
Human lipodystrophies are a heterogeneous group of diseases with generalized or partial
fat loss. They include rare genetic conditions or more frequent acquired forms, and may be
old, or more recent, such as HIV-related lipodystrophy. Almost all lipodystrophies are asso‐
ciated with metabolic alterations including IR, diabetes, dyslipidemia and early CV disease.
In this new context of increased aging of HIV-infected patients, increased metabolic and CV
complications are to be expected due to high incidences of smoking status, over-nutrition
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and reduced exercise, lipodystrophy, dyslipidemia, altered glucose tolerance with IR and
low-grade infection with the ongoing drug-induced inflammation. It is important to be
aware of these alterations and to apply risk-modification strategies to reduce CV risk in the
HIV-infected patients.
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